GlassScriptPhysician profile
Dorian Noguera
NPI 1649383449
$2,896.72
in general payments reported to CMS, 2019-2025
15 companies · $473 in 2025
The $473 reported for 2025 was more than what 83% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $201 · 2021: $212 · 2022: $439 · 2023: $387 · 2024: $473 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,160.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Biocryst US Sales Co., LLC | $766.34 | 2022-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $295.15 | 2019-2021 | |
| Pbg Puerto Rico LLC | $154.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $148.48 | 2019-2022 | |
| Mylan Specialty L.P. | $105.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.20 | 2021-2024 | Jardiance |
| Pfizer Pharmaceuticals LLC | $40.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.91 | 2019-2023 | Xarelto, Invokana |
| Viiv Healthcare Company | $25.00 | 2024 | Dovato |
| Biohaven Pharmaceutical Holding Company LTD. | $24.61 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.00 | 2022 | |
| Genentech USA, INC. | $20.00 | 2019 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $19.00 | 2022 | |
| Mylan LLC | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorian Noguera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.